First Wave BioPharma

About First Wave BioPharma

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted, orally delivered therapies for gastrointestinal (GI) diseases. The company addresses a range of clinical indications, including nutritional disorders and autoimmune-related diseases. Their pipeline targets digestive disorders such as celiac disease, gastroparesis, exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients, and inflammatory bowel diseases like ulcerative colitis. First Wave BioPharma's product portfolio includes three proprietary technologies: Capeserod, a selective 5-HT4 receptor partial agonist for GI indications; Adrulipase, a recombinant lipase enzyme designed to aid in the digestion of fats and other nutrients; and Niclosamide, an oral small molecule with anti-inflammatory properties. The company primarily serves patients suffering from GI diseases, aiming to alleviate their symptoms, protect their health, and restore their quality of life. Operating in the biopharmaceutical market, First Wave BioPharma generates revenue through the development and potential commercialization of its proprietary therapies. Keywords: gastrointestinal, biopharmaceutical, clinical-stage, therapies, celiac disease, gastroparesis, exocrine pancreatic insufficiency, inflammatory bowel disease, Capeserod, Adrulipase.